Active Biotech: Notice of Annual General Meeting of Shareholders

LUND, Sweden, April 26, 2016 -- The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 26, 2016, at 5 pm at Elite Hotel Ideon, Scheelevägen 27 in Lund, Sweden.

Please see the attached notification, which is being announced within short in Svenska Dagbladet and Post- och Inrikes Tidningar.

Lund, April 26, 2016

ACTIVE BIOTECH AB (PUBL)
THE BOARD OF DIRECTORS

 
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the ISI, ANYARA and paquinimod projects. Please visit www.activebiotech.com for more information.
 

Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 05

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. This information was provided to the media for publication at 8:30 am CET on April 26, 2016.

160426 Invitation AGM 2016_ENG http://hugin.info/1002/R/2006457/741349.pdf

HUG#2006457